No Cover Image

Journal article 534 views 51 downloads

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

Stefania Chiappini Orcid Logo, Rachel Vickers-Smith Orcid Logo, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery Orcid Logo, Amira Guirguis Orcid Logo, Giovanni Martinotti Orcid Logo, Stefano L. Sensi, Fabrizio Schifano

Pharmaceuticals, Volume: 16, Issue: 7, Start page: 994

Swansea University Author: Amira Guirguis Orcid Logo

  • 63918.VOR.pdf

    PDF | Version of Record

    © The Author(s) 2023. Licensee MDPI, Basel, Switzerland. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).

    Download (1.89MB)

Check full text

DOI (Published version): 10.3390/ph16070994

Abstract

Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, in...

Full description

Published in: Pharmaceuticals
ISSN: 1424-8247
Published: UK MDPI AG 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63918
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-07-19T17:00:46Z
last_indexed 2023-07-19T17:00:46Z
id cronfa63918
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>63918</id><entry>2023-07-19</entry><title>Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset</title><swanseaauthors><author><sid>b49270b9a0d580cf4f31f9a1b6c93f87</sid><ORCID>0000-0001-8255-0660</ORCID><firstname>Amira</firstname><surname>Guirguis</surname><name>Amira Guirguis</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-07-19</date><deptcode>PHAR</deptcode><abstract>Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, in comparison to other GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and tirzepatide) and the phentermine–topiramate combination. To acheieve that aim, we analyzed the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) dataset, performing a descriptive analysis of adverse event reports (AERs) and calculating related pharmacovigilance measures, including the reporting odds ratio (ROR) and the proportional reporting ratio (PRR). During January 2018–December 2022, a total of 31,542 AERs involving the selected molecules were submitted to FAERS; most involved dulaglutide (n = 11,858; 37.6%) and semaglutide (n = 8249; 26.1%). In comparing semaglutide vs. the remaining molecules, the respective PRR values of the AERs ‘drug abuse’, ‘drug withdrawal syndrome’, ‘prescription drug used without a prescription’, and ‘intentional product use issue’ were 4.05, 4.05, 3.60, and 1.80 (all &lt; 0.01). The same comparisons of semaglutide vs. the phentermine–topiramate combination were not associated with any significant differences. To the best of our knowledge, this is the first study documenting the misuse/abuse potential of semaglutide in comparison with other GLP1 analogues and the phentermine–topiramate combination. The current findings will need to be confirmed by further empirical investigations to fully understand the safety profile of those molecules.</abstract><type>Journal Article</type><journal>Pharmaceuticals</journal><volume>16</volume><journalNumber>7</journalNumber><paginationStart>994</paginationStart><paginationEnd/><publisher>MDPI AG</publisher><placeOfPublication>UK</placeOfPublication><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1424-8247</issnElectronic><keywords>Semaglutide, drug misuse, drug abuse, pharmacovigilance, image- and performance enhancing drugs (IPEDs), glucagon-like peptide-1 (GLP-1) agonists</keywords><publishedDay>11</publishedDay><publishedMonth>7</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-07-11</publishedDate><doi>10.3390/ph16070994</doi><url>http://dx.doi.org/10.3390/ph16070994</url><notes/><college>COLLEGE NANME</college><department>Pharmacy</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PHAR</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2023-08-22T14:55:10.9881492</lastEdited><Created>2023-07-19T17:52:36.5798567</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>Stefania</firstname><surname>Chiappini</surname><orcid>0000-0002-6810-1540</orcid><order>1</order></author><author><firstname>Rachel</firstname><surname>Vickers-Smith</surname><orcid>0000-0002-7224-8916</orcid><order>2</order></author><author><firstname>Daniel</firstname><surname>Harris</surname><order>3</order></author><author><firstname>G. Duccio Papanti</firstname><surname>Pelletier</surname><order>4</order></author><author><firstname>John Martin</firstname><surname>Corkery</surname><orcid>0000-0002-3849-817x</orcid><order>5</order></author><author><firstname>Amira</firstname><surname>Guirguis</surname><orcid>0000-0001-8255-0660</orcid><order>6</order></author><author><firstname>Giovanni</firstname><surname>Martinotti</surname><orcid>0000-0002-7292-2341</orcid><order>7</order></author><author><firstname>Stefano L.</firstname><surname>Sensi</surname><order>8</order></author><author><firstname>Fabrizio</firstname><surname>Schifano</surname><order>9</order></author></authors><documents><document><filename>63918__28343__438a8b37522a40c59d4b21a6339e8cf6.pdf</filename><originalFilename>63918.VOR.pdf</originalFilename><uploaded>2023-08-22T14:51:38.1395296</uploaded><type>Output</type><contentLength>1983736</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© The Author(s) 2023. Licensee MDPI, Basel, Switzerland. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 63918 2023-07-19 Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset b49270b9a0d580cf4f31f9a1b6c93f87 0000-0001-8255-0660 Amira Guirguis Amira Guirguis true false 2023-07-19 PHAR Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, in comparison to other GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and tirzepatide) and the phentermine–topiramate combination. To acheieve that aim, we analyzed the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) dataset, performing a descriptive analysis of adverse event reports (AERs) and calculating related pharmacovigilance measures, including the reporting odds ratio (ROR) and the proportional reporting ratio (PRR). During January 2018–December 2022, a total of 31,542 AERs involving the selected molecules were submitted to FAERS; most involved dulaglutide (n = 11,858; 37.6%) and semaglutide (n = 8249; 26.1%). In comparing semaglutide vs. the remaining molecules, the respective PRR values of the AERs ‘drug abuse’, ‘drug withdrawal syndrome’, ‘prescription drug used without a prescription’, and ‘intentional product use issue’ were 4.05, 4.05, 3.60, and 1.80 (all < 0.01). The same comparisons of semaglutide vs. the phentermine–topiramate combination were not associated with any significant differences. To the best of our knowledge, this is the first study documenting the misuse/abuse potential of semaglutide in comparison with other GLP1 analogues and the phentermine–topiramate combination. The current findings will need to be confirmed by further empirical investigations to fully understand the safety profile of those molecules. Journal Article Pharmaceuticals 16 7 994 MDPI AG UK 1424-8247 Semaglutide, drug misuse, drug abuse, pharmacovigilance, image- and performance enhancing drugs (IPEDs), glucagon-like peptide-1 (GLP-1) agonists 11 7 2023 2023-07-11 10.3390/ph16070994 http://dx.doi.org/10.3390/ph16070994 COLLEGE NANME Pharmacy COLLEGE CODE PHAR Swansea University 2023-08-22T14:55:10.9881492 2023-07-19T17:52:36.5798567 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy Stefania Chiappini 0000-0002-6810-1540 1 Rachel Vickers-Smith 0000-0002-7224-8916 2 Daniel Harris 3 G. Duccio Papanti Pelletier 4 John Martin Corkery 0000-0002-3849-817x 5 Amira Guirguis 0000-0001-8255-0660 6 Giovanni Martinotti 0000-0002-7292-2341 7 Stefano L. Sensi 8 Fabrizio Schifano 9 63918__28343__438a8b37522a40c59d4b21a6339e8cf6.pdf 63918.VOR.pdf 2023-08-22T14:51:38.1395296 Output 1983736 application/pdf Version of Record true © The Author(s) 2023. Licensee MDPI, Basel, Switzerland. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0). true eng https://creativecommons.org/licenses/by/4.0/
title Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
spellingShingle Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
Amira Guirguis
title_short Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
title_full Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
title_fullStr Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
title_full_unstemmed Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
title_sort Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
author_id_str_mv b49270b9a0d580cf4f31f9a1b6c93f87
author_id_fullname_str_mv b49270b9a0d580cf4f31f9a1b6c93f87_***_Amira Guirguis
author Amira Guirguis
author2 Stefania Chiappini
Rachel Vickers-Smith
Daniel Harris
G. Duccio Papanti Pelletier
John Martin Corkery
Amira Guirguis
Giovanni Martinotti
Stefano L. Sensi
Fabrizio Schifano
format Journal article
container_title Pharmaceuticals
container_volume 16
container_issue 7
container_start_page 994
publishDate 2023
institution Swansea University
issn 1424-8247
doi_str_mv 10.3390/ph16070994
publisher MDPI AG
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy
url http://dx.doi.org/10.3390/ph16070994
document_store_str 1
active_str 0
description Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, in comparison to other GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and tirzepatide) and the phentermine–topiramate combination. To acheieve that aim, we analyzed the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) dataset, performing a descriptive analysis of adverse event reports (AERs) and calculating related pharmacovigilance measures, including the reporting odds ratio (ROR) and the proportional reporting ratio (PRR). During January 2018–December 2022, a total of 31,542 AERs involving the selected molecules were submitted to FAERS; most involved dulaglutide (n = 11,858; 37.6%) and semaglutide (n = 8249; 26.1%). In comparing semaglutide vs. the remaining molecules, the respective PRR values of the AERs ‘drug abuse’, ‘drug withdrawal syndrome’, ‘prescription drug used without a prescription’, and ‘intentional product use issue’ were 4.05, 4.05, 3.60, and 1.80 (all < 0.01). The same comparisons of semaglutide vs. the phentermine–topiramate combination were not associated with any significant differences. To the best of our knowledge, this is the first study documenting the misuse/abuse potential of semaglutide in comparison with other GLP1 analogues and the phentermine–topiramate combination. The current findings will need to be confirmed by further empirical investigations to fully understand the safety profile of those molecules.
published_date 2023-07-11T14:55:11Z
_version_ 1774937714797314048
score 11.037581

Similar Items